TKMR, Tekmira Pharmaceuticals Corp.

** TKMR reported that the United States Patent & Trademark Office (USPTO) has recently issued two key patents expanding its intellectual property portfolio: one covers its lipid nanoparticle (LNP) delivery technology (U.S. Patent No. 8,058,069), and the other covers the chemical modification of siRNA to mitigate immune stimulation (U.S. Patent No. 8,101,741).

With the issuance of U.S. Patent No. 8,058,069, the USPTO has granted claims covering certain ratios of lipids used in TKMR’s LNP formulations, which have shown to impart increased drug activity and improved tolerability of the formulations in vivo, which result in a significant increase in the therapeutic index as compared to other compositions.

With the issuance of U.S. Patent No. 8,101,741, the USPTO has granted claims covering the chemical modification of siRNA sequences to prevent immune stimulation. This intellectual property is based on research by TKMR’s scientists regarding the stimulation of the innate immune system by nucleic acids, including siRNA.

TKMR is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners.

RNAi therapeutics have the potential to treat a broad number of human diseases by “silencing” disease causing genes. RNAi therapeutics, such as “siRNAs,” require delivery technology to be effective systemically.

More about TKMR at www.tekmirapharm.com.

**********

SPRT, Support.com Incorporated

** For the fourth quarter of 2011, SPRT posted total revenue of $15.0 million compared to $12.4 million in the previous quarter and $12.3 million in the same period the prior year

SPRT provides cloud-based technology services and software for consumers and small business.

More about SPRT at www.support.com

**********

THOR, Thoratec Corporation

** THOR reported fourth quarter fiscal 2011 financial results, posting revenues of $109.4 million, a 12% increase year over year, and net income on a GAAP basis of $15.3 million, or $0.25 per diluted share, versus GAAP net income of $12.6 million, or $0.21 per diluted share, in the same period a year ago.

THOR is a world leader in therapies to address advanced-stage heart failure. The company’s products include the HeartMate LVAS (Left Ventricular Assist System) and Thoratec VAD (Ventricular Assist Device) with more than 18,000 devices implanted in patients suffering from heart failure.

More about THOR at www.thoratec.com.

**********

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.